The company made this announcement during trading hours on Wednesday, 23 May 2012. The stock had fallen 2.22% to settle at Rs 107.70 on that day in a weak market.

Meanwhile, the BSE Sensex was up 221.39 points or 1.39% to 16,169.49.

On BSE, 48,000 shares were traded in the counter as against average daily volume of 2.26 lakh shares in the past one quarter.

The stock hit high of Rs 111.95 and a low of Rs 109.05 so far during the day. The stock had hit a 52-week high of Rs 188.85 on 27 July 2011. The stock had hit a 52-week low of Rs 80.35 on 18 November 2011.

The mid-cap stock had underperformed the market over the past one month till 23 May 2012, falling 16.28% compared with the Sensex's 6.72% fall. The scrip had, however, outperformed the market in past one quarter, declining 4.73% as against Sensex's 11.78% decline.

The company has an equity capital of Rs 29.11 crore. Face value per share is Re 1.

Aurobindo Pharma said its tentatively approved abbreviated new drug applications (ANDA) for Nevirapine Tablets 200 milligram (mg) and Nevirapine Oral Suspension 50 mg/5 mL have received the final approval from the US Food and Drug Administration (USFDA). According to IMS data, the products had a market size of approximately $125 million in the US for the 12 months ended December 2011.

Nevirapine Tablets 200 mg and Nevirapine Oral Suspension 50 mg/5 mL are the generic equivalent of Boehringer Ingelheim Pharmaceutical Inc's Viramune Tablets 200 mg and Oral Suspension 50 mg/5 mL. The products are indicated as part of antiretroviral (ARV) combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults.

Nevirapine Tablets 200 mg and Nevirapine Oral Suspension 50 mg/5 mL have been approved out of Unit III formulations facility in Hyderabad and will be launched soon, Aurobindo Pharma said in a statement.

Aurobindo now has a total of 151 ANDA approvals (125 final approvals including 1 from Aurolife Pharma LLC and 26 tentative approvals) from USFDA, the company said.

On a consolidated basis, Aurobindo Pharma reported net loss of Rs 28.54 crore for Q3 December 2011, compared with net profit of Rs 188.63 crore in Q3 December 2010. Net sales rose 7.7% to Rs 1284.51 crore in Q3 December 2011 over Q3 December 2010. The company unveils FY 2012 results on 29 May 2012.

Aurobindo Pharma, headquartered at Hyderabad, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's product portfolio is spread over 6 major therapeutic/product areas encompassing CVS, CNS, anti-retroviral, antibiotics, gastroenterologicals, antibiotics and anti-allergic. The company is marketing these products globally in over 125 countries. The company's manufacturing facilities are approved by regulatory agencies like USFDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil.